Safety of concurrent administration of dexrazoxane and doxorubicin in the canine cancer patient

Simple item page
dc.contributor.authorFitzPatrick, W. M.en
dc.contributor.authorDervisis, Nikolaos G.en
dc.contributor.authorKitchell, B. E.en
dc.date.accessioned2016-11-15T20:50:13Zen
dc.date.available2016-11-15T20:50:13Zen
dc.date.issued2010-12-01en
dc.description.abstractDoxorubicinmay cause a rare but serious cardiotoxicity. Dexrazoxane is a cardioprotectant drug used to reduce the risk of cardiotoxicity in human patients. In this study, 25 tumour-bearing dogs were treated with concurrent doxorubicin and dexrazoxane. The total number of doses of dexrazoxane given was 54 (range 1–5 doses per dog, median 2 doses). Five dogs receivedmore than 165 mg m<sup>2</sup> cumulative doxorubicin dose before starting dexrazoxane. Haematologic, gastrointestinal and cardiovascular toxicities were considered tolerable. The combination of doxorubicin with dexrazoxane was well tolerated with minimal side-effects in this patient cohort. Future studies are required to evaluate potential cardioprotective effects of dexrazoxane given concurrently with doxorubicin.en
dc.description.versionPublished versionen
dc.format.extent273 - 282 (10) page(s)en
dc.format.mimetypeapplication/pdfen
dc.identifier.doihttps://doi.org/10.1111/j.1476-5829.2010.00225.xen
dc.identifier.issn1476-5810en
dc.identifier.issue4en
dc.identifier.urihttp://hdl.handle.net/10919/73461en
dc.identifier.volume8en
dc.language.isoenen
dc.publisherWiley-Blackwellen
dc.relation.urihttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000283988700004&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=930d57c9ac61a043676db62af60056c1en
dc.rightsIn Copyrighten
dc.rights.urihttp://rightsstatements.org/vocab/InC/1.0/en
dc.subjectVeterinary Sciencesen
dc.subjectchemotherapyen
dc.subjectdexrazoxaneen
dc.subjectdoxorubicinen
dc.subjecttoxicityen
dc.subjectLEFT-VENTRICULAR DYSFUNCTIONen
dc.subjectDNA TOPOISOMERASE-IIen
dc.subjectANTHRACYCLINE ANTIBIOTICSen
dc.subjectHEART-FAILUREen
dc.subjectCARDIOTOXICITYen
dc.subjectADRIAMYCINen
dc.subjectCARDIOMYOPATHYen
dc.subjectDAUNORUBICINen
dc.subjectETOPOSIDEen
dc.subjectICRF-187en
dc.titleSafety of concurrent administration of dexrazoxane and doxorubicin in the canine cancer patienten
dc.title.serialVeterinary and Comparative Oncologyen
dc.typeArticle - Refereeden
dc.type.dcmitypeTexten
pubs.organisational-group/Virginia Techen
pubs.organisational-group/Virginia Tech/All T&R Facultyen
pubs.organisational-group/Virginia Tech/Faculty of Health Sciencesen
pubs.organisational-group/Virginia Tech/Veterinary Medicineen
pubs.organisational-group/Virginia Tech/Veterinary Medicine/CVM T&R Facultyen
pubs.organisational-group/Virginia Tech/Veterinary Medicine/Small Animal Clinical Sciencesen

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Safety of concurrent administration of dexrazoxane and doxorubicin in the canine cancer patient.pdf
Size:
514.07 KB
Format:
Adobe Portable Document Format
Description:
Published version
Download
License bundle
Now showing 1 - 1 of 1
Name:
VTUL_Distribution_License_2016_05_09.pdf
Size:
18.09 KB
Format:
Adobe Portable Document Format
Description:
Download

Collections

All Faculty Deposits
Scholarly Works, Small Animal Clinical Sciences